Pharmalyst (Pharmalyst@gmail.com)

Popular pages

• Pharmalyst (Pharmalyst@gmail.com)

  The demise of Exubera has received a lot of insightful & funny coverage in various blogs that Pharmalyst reads (PharmaGiles, PharmaGossip, Pharmalot, Pharma Marketing Blog etc). Pharmalot's redaders h...

• Pharmalyst (Pharmalyst@gmail.com): May 2007

  Well, my little poll was not of much help in guesstimating the price of this product in China (too few & scattered responses - but thanks anyway!). Pharmalyst was initially thinking that the price wou...

• Pharmalyst (Pharmalyst@gmail.com): Pricing of Pfizer's Maraviroc

  The FDA advisory committee approval of Pfizer's CCR5 pathway-based HIV drug Maraviroc was widely covered in the media. While analysts and do...

• Pharmalyst (Pharmalyst@gmail.com): Prospects for Oral Factor Xa Inhibitors Rivaroxaban, Apixaban

  During the past couble of months, many of you have found Pharmayst's little blog by typing in phrases like "rivaroxaban peak sales" and "api...

• Pharmalyst (Pharmalyst@gmail.com): Rivaroxaban, Apixaban - Meeting unmet needs and prospects (parts

  Pharmalyst had previously posted re oral factor Xa inhibitors. Pharmalyst had promised readers parts 2 & 3 outlining unmet needs in this mar...

• Pharmalyst (Pharmalyst@gmail.com): July 2007

  Thanks to Dr. Peter Rost's blog, I just became aware an interesting blog called PharmaFraud. S/he has written a rather interesting and provocative rant about some pharmablogs. About the PharmaBlogosph...